VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > CEO interview

<< Previous

Bullboard Posts

Next >>

Post by KChitsdingerson Nov 20, 2020 6:54pm

1106 Views

Post# 31945635

CEO interview

Interview was informative and the company has made progress since he last spoke publicly. Up to 2 0 units for 2020 and up to 100 installed in 2021. What interested me is the takeout price for new innovation ultrasound companies. He said starting at 100 m and could go as high as a billion. What does that translate in share price for shareholders ? I am in this for the long haul and believe in the product . Thanx

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 13, 2024